Jul. 16 at 7:27 PM
$IMDX The Medicare policy released today is Christmas in July for molecular transplanted organ health monitoring,” iMDx CEO Josh Riggs said. “We are encouraged to see that CMS was responsive to the voices of the clinical community and increased the allowed amount of testing like ours.”
iMDx believes the favorable policy provides additional clarity for hospitals, clinicians, and laboratories, supports patient access to reimbursable dd-cfDNA testing, and further aligns with the company's strategy to enable in-house dd-cfDNA testing.
